Valuation : Vertex Pharmaceuticals Incorporated

Market Cap 14TCr 12TCr 11TCr 10TCr 19TCr 13,11300Cr 19TCr 1,33600Cr 52TCr 6,70400Cr 52TCr 51TCr 22,02200Cr P/E 2026 *
32.3x
P/E 2027 * 26.4x
Enterprise Value 13TCr 11TCr 10TCr 9.49TCr 18TCr 12,10800Cr 18TCr 1,23300Cr 48TCr 6,19000Cr 48TCr 47TCr 20,33500Cr EV / Sales 2026 *
9.72x
EV / Sales 2027 * 8.42x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
1 day+1.64%
1 week+1.47%
Current month+1.99%
1 month+17.98%
3 months+30.64%
6 months+14.26%
Current year+22.49%
1 week 532.23
Extreme 532.2281
557.5
1 month 465.51
Extreme 465.51
557.5
Current year 412.27
Extreme 412.27
557.5
1 year 374.17
Extreme 374.17
557.5
3 years 340.83
Extreme 340.83
557.5
5 years 176.36
Extreme 176.36
557.5
10 years 71.46
Extreme 71.46
557.5
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2020
Director of Finance/CFO 57 10/04/2019
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 66 01/01/1998
Chairman 70 01/05/2012
Director/Board Member 57 18/06/2015
Date Insider Type Main position Quantity % Market Cap. Importance
27/08/26 Don

Director

-6,000 0.0024%
21/07/26 Free

General Counsel

8,251 0.0033%
21/07/26 Free

Public Communications Manager

8,251 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%+1.47%+38.49%+59.46% 14TCr
+0.19%-2.04%+58.48%+108.73% 1,03400Cr
+1.66%+1.99%+54.64%+71.37% 65TCr
+0.43%-0.75%+23.12%+78.59% 46TCr
+0.49%-5.19%+33.28%+35.53% 34TCr
+0.27%+3.26%+29.76%+47.50% 31TCr
+0.12%-2.11%+0.60%+12.03% 25TCr
+0.85%+0.27%+53.89%+73.83% 24TCr
+2.64%-1.08%-15.85%-53.97% 20TCr
-0.08%+0.91%+32.59%+98.83% 19TCr
Average +0.82%-2.69%+30.90%+53.19% 38.1TCr
Weighted average by Cap. +0.71%-3.23%+38.96%+67.75%

Financials

2026 *2027 *
Net sales 1.32TCr 1.14TCr 1.07TCr 976.87Cr 1.83TCr 1,24600Cr 1.84TCr 13TCr 4.93TCr 64TCr 4.95TCr 4.85TCr 2,09300Cr 1.46TCr 1.26TCr 1.19TCr 1.08TCr 2.02TCr 1,38000Cr 2.04TCr 14TCr 5.45TCr 71TCr 5.49TCr 5.37TCr 2,31800Cr
Net income 430.57Cr 371.45Cr 349.91Cr 318.81Cr 595.91Cr 41TCr 600.38Cr 4.14TCr 1.61TCr 21TCr 1.62TCr 1.58TCr 68TCr 522.79Cr 451.01Cr 424.86Cr 387.1Cr 723.55Cr 49TCr 728.98Cr 5.03TCr 1.95TCr 25TCr 1.96TCr 1.92TCr 83TCr
Net Debt -1.06TCr -917.44Cr -864.25Cr -787.44Cr -1.47TCr -1,00500Cr -1.48TCr -10TCr -3.97TCr -51TCr -3.99TCr -3.91TCr -1,68700Cr -1.58TCr -1.36TCr -1.28TCr -1.17TCr -2.18TCr -1,49100Cr -2.2TCr -15TCr -5.89TCr -76TCr -5.93TCr -5.8TCr -2,50500Cr
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
03/26/03 $555.10 +1.36% 12,15,630
01/26/01 $547.65 +0.57% 7,35,119
31/26/31 $544.52 +0.52% 11,98,447
28/26/28 $541.69 -1.07% 8,86,917
27/26/27 $547.55 +0.05% 8,44,619
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
547.65USD
Average target price
567.04USD
Spread / Average Target
+3.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock